BioMarin Pharmaceuticals, Inc. (BMRN) Tops Q2 EPS by 6c; Guides FY11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500 set for muted open after big bank earnings, chip slide weighs
- Oil eases as traders monitor Russian diesel deal, Saudi attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $55.39 --0%
EPS Growth %: +1,008.3%
Financial Fact:
Provision for income taxes: -24.02M
Today's EPS Names:
PGR, OMID, ACI, More
EPS Growth %: +1,008.3%
Financial Fact:
Provision for income taxes: -24.02M
Today's EPS Names:
PGR, OMID, ACI, More
Join SI Premium – FREE
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q2 EPS of ($0.05), $0.06 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $110.63 million versus the consensus estimate of $105.9 million.
Sees FY2011 revenue of $436-$465 million, versus prior guidance of $422-$452 million and the consensus of $441.08 million.
Sees FY2011 revenue of $436-$465 million, versus prior guidance of $422-$452 million and the consensus of $441.08 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Strong Buy
- Citigroup (C) Tops Q3 EPS by 20c
- Goldman Sachs (GS) Tops Q3 EPS by $3.92
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
